Archive for September 2020
Immunexpress Identifies and Validates Blood Transcriptomic Signatures for Discrimination of Viral and Bacterial Infections in the Emergency Department
Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients SEATTLE, Sept. 23, 2020 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today new data in collaboration with researchers at the University College of London. …
Read MoreImmunexpress Presents Data on Clinical Validation of SeptiCyte® RAPID for Diagnosing Sepsis at e-ISICEM
Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled “Clinical Performance of a Rapid Sepsis…
Read MoreImmunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch
Immunexpress and its partner Biocartis plan to introduce a new, rapid test for sepsis in Europe this quarter ahead of a potential US Food and Drug Administration 510(k) clearance for the assay later this year. The companies are positioning the test, called SeptiCyte Rapid, to triage COVID-19 patients who could be at greater risk for…
Read More